



Evolution Research Group Letter from the CEO

Version Date: May 1, 2020

Dear ERG Trusted Partner,

On behalf of our team at ERG, I want to first and foremost extend our gratitude for those of you who are working bravely on the front lines of the COVID-19 pandemic, or have sons, daughters, parents, siblings, cousins and/or friends who have put their lives in harm's way to combat this virus. Our thoughts extend to anyone who has suffered the loss of a loved one or that has endured the fear of a negative outcome by receiving a positive test result.

As you are likely aware, ERG has been extremely proactive in its approach to the management of the COVID-19 pandemic and to ensuring the safety of study subjects, staff and others involved in the execution of its clinical trials across all sites. I am extremely proud of how our ERG team has assembled to advance our pandemic planning process to determine how to mitigate current risks by amending study processes and/or procedures. We have finalized ERG's site-specific **COVID-19 Risk Mitigation and Recovery Plans** and am thankful for how quickly our response has progressed. These plans are available for download on this website by clicking [here](#). Revisions will be posted, as necessary.

All our ERG sites continue to operate under their individualized plans. ERG remains dedicated to ensuring our data quality standards are not affected by the current situation. We have been fortunate that some of our sites are operating in areas that were not impacted as severely as others.

Unfortunately, some of ERG's portfolio and affiliate sites operate in "hot spots" in New York and Florida. We had to act quickly and carefully to move to conducting primarily "**remote visits**" for brief periods at some of these locations. We have been in constant direct contact with our study sponsors, working together to find alternative approaches to maintain trial participant safety and trial data quality and integrity.

ERG has invested substantial time, training and financial resources to building a solid infrastructure that can easily pivot to working in a remote environment. Our Senior Leadership Team, PIs and Site Directors have done a stellar job accelerating expanded training around each of our technology platforms. All our ERG sites are now trained and currently utilizing our internal system for all **Remote Monitoring Visits**, for which our clients are most grateful. We have provided ERG's **Remote Monitoring Visit Policy**, for download on our website [here](#).

We have finalized our "Corporate Guidance: Remote Study Visits During COVID-19 Pandemic." These plans are available for download on this website by clicking [here](#). Revisions will be posted, as necessary. For additional information regarding our use of technology, compliance and quality standards or our operating procedures, including our use of **telemedicine, remote visits (phone and video), remote pre-screening and consenting, home health care/home visits**, please review our **ERG COVID-19 Frequently Asked Questions** on our website [here](#).



If you have any additional questions, I invite you to email Andria Chastain, our Chief Operating Officer. If you would like to schedule a call with members of ERG's Sr. Leadership Team including Dave Hennessy (CIO), Dr. Daniel Gruener (CMO) and Caroline "Carrie" Cassidy (VP of Quality Assurance & Compliance) and others to discuss your specific needs, please email Andria or me and we will schedule something within 24-48 hours.

Clear, concise and continuous communications are most critical during this time, and we will provide updates, as necessary. In the meantime, please be assured that ERG remains committed to keeping everyone safe and healthy while conducting research studies and we will continue following all necessary federal, state and local guidance and guidelines.

Please stay safe and healthy and feel free to contact me anytime at lthievonwright@ergclinical.com.

Regards,
Lori Wright